癌症生物学与医学（英文版）（Cancer Biology & Medicine） 知网万方维普

期刊简介

《癌症生物学与医学（英文版）（Cancer Biology & Medicine）》期刊已被查看： 次

更新频次

单位占比

一作占比

投稿指南

1、投稿方式：在线投稿。

2、刊内网址：http://www.cancerbiomed.org/

3、刊内邮箱：editor@cancerbiomed.org

4、刊内电话：022-23522919

5、出刊日期：月刊，一年出版12期。

2021年5月11日星期二

《癌症生物学与医学（英文）》投稿须知

【官网信息】

Instructions for Authors

ABOUT THE JOURNAL

Cancer

Biology & Medicine is a peer-reviewed open-access journal sponsored

by the China Anti-cancer Association (CACA), which is the leading

professional society of oncology in China, and Tianjin Medical

University Cancer Institute and Hospital (TMUCIH). Published quarterly,

the journal provides innovative and significant information on

biological basis of cancer, cancer microenvironment, translational

cancer research, and all aspects of clinical cancer research. The

journal also publishes significant perspectives on indigenous cancer

types in China. The journal adheres to the Recommendations for the

Conduct, Reporting, Editing, and Publication of Scholarly Work in

Medical Journals, issued by the International Committee for Medical

Journal Editors (ICMJE) and the guidelines of Committee on Publication

Ethics (COPE).

Aims and Scope

Cancer

Biology & Medicine is dedicated to reporting latest advances in

cancer research around the world by presenting high quality articles,

especially on translational cancer research, to bridge the gap between

basic and clinical cancer research. Meanwhile, the journal promotes

academic exchange in cancer area between China and the rest of the world

to keep cancer researchers and clinicians updated with current

knowledge of novel findings and recent advances in oncology. The scope

covers the following topics:

● Cancer genetics

● Cancer and stem cell biology

● Molecular and clinical immunology

● Cancer prevention and epidemiology

● Cancer biomarkers

● Radiation oncology

● Oncology clinical trials

● Mechanisms of drug sensitivity and resistance

● Targeted therapy and immunotherapy

● Multidisciplinary treatment and personalized medicine

AUDIENCE

Cancer

Biology & Medicine endeavors to appeal a diverse audience engaged

in cancer research and subspecialties in clinical oncology. Readers may

include, but not limited to, investigators, physicians, surgeons and

nurses in cancer research areas, medical students, and other relevant

health care professionals.

CONTENT CATEGORIES

Original Article, Editorial, Perspective, Review, Minireview, Letter to the Editor, Practice Guideline, and MDT Case Study.

INDEXING INFORMATION

Cancer

Biology & Medicine is indexed in SCIE, PubMed/PubMed Central,

BIOSIS Previews, EMBASE, SCOPUS, EBSCO, DOAJ, and Chemical Abstracts.

EDITORIAL POLICIES

Authorship and Contributorship

Authorship

credit should be based on 1) substantial contributions to conception

and design, acquisition of data, or analysis and interpretation of data;

2) drafting the article or revising it critically for important

intellectual content; and 3) final approval of the version to be published. The manuscript’s

content and its submission for publication should be approved by all

authors who should sign off in the author form prior to submission.

Revisions and final version should be

approved by all authors. Contributors who do not meet the criteria for

authorship should be listed in the Acknowledgments section.

Except

for ensuring that authors are appropriately listed and providing

information on the specific contributions each author has made to the

article, the corresponding author is also required to offer the Open

Researcher and Contributor Identifier (ORCID) ID before proceeding with

submission. He/she could register an account of ORCID via this link:

https://orcid.org/. By the way, please be aware that all communication

during the submission and publishing process will be sent to the

corresponding author. Co-first authors and co-corresponding authors are

acceptable, but no more than 2. In cases with co-corresponding authors, a

primary one must be designated as the point of contact responsible for

all communication and will be listed firstly.

Ethics Involving Humans and Animals

The

welfare of animals used for research must be respected. Animal

experiments should abide by the institutional and national guide for the

care and use of laboratory animals. For primary research manuscripts in

Cancer Biology & Medicine reporting experiments on animals, the

authors must confirm that all experiments were performed in accordance

with relevant guidelines and regulations. Manuscripts must include a

statement in materials and methods section that the research has been

reviewed and approved by institutional ethical committee before

conduction.

Experiments

on human subjects should follow the Helsinki Declaration (as revised in

2013) and should be approved by an ethics committee. Concerning privacy

and/or security of personal information, informed consents and

permissions must be obtained in regard to case details, personal

information, and/or images used. When reporting studies that involve

human participants, authors should include a statement that the studies

have been approved by the appropriate institutional and/or national

research ethics committee and have been conducted in accordance with

Declaration of Helsinki. For manuscripts reporting biomedical research

involving human subjects, a statement that the informed consent was

obtained from each subject is required. If the study is a clinical

trial, the trial must be registered in an appropriate registry prior to

the start of the trial. Authors should provide ClinicalTrials.gov

Identifier in the manuscript.

For

all research involving human subjects, informed consent should be

obtained from participants or their legal guardian and a statement to

this effect should appear in the manuscript. Informed consent must

comply with all applicable laws and regulations concerning the privacy

and/or security of personal information. Patients' names, initials,

social security numbers, dates of birth or other personal or identifying

information should not be used. Images of patients should not be used

unless the information is essential for scientific purposes and explicit

permission has been given as part of the consent. Identifying details

should be omitted if they are not essential.

Conflict of Interest

Conflict of interest exists when an author (or the author’s institution), reviewer, or editor has any financial or personal relationships that may inappropriately influence (bias) his or her actions. Cancer Biology

& Medicine requires all authors to disclose any relationship that

might result in an actual, potential, or perceived conflict of interest

about the manuscript submitted for review. Reviewers and editors should

also disclose all relationships that may undermine the credibility of

the publication process. Conflict of Interest Statement should be

written as a section before References.

Exclusive Submission

Manuscripts

are considered for review only if no part of the work has been

previously published in print or electronically. Previous publication of

an abstract in the proceedings of meetings does not preclude whole

manuscript submission for publication, but full disclosure should be

made. At submission, the corresponding author is responsible to attest

that the manuscript, in whole or in part, is not under consideration, in

press, or published in any other publication or electronic medium.

Copyright and Permissions

If

a manuscript includes copyrighted materials of others, authors must

obtain written permission from the copyright owners and indicate the

sources in the article. The written permission should be simultaneously

submitted with the manuscript.

Checking for Scientific Misconduct

Cancer

Biology & Medicine has an obligation to ensure that its published

articles are accurate and adheres to the highest ethical standard.

Editors check all submissions using CrossCheck. In the cases of

plagiarism, redundant or duplicate publication, the journal will send a

letter of reprimand to the authors’ institution, publish a notice of

misconduct and formally retract the published manuscript. The journal

will remove further association with the involved authors and

institutions.

Peer Review

After

initial review by the editor or sometimes by an editorial board member,

manuscripts without sufficient priority for publication will be

editorially rejected within 7 days. Those qualifying for peer review

will be sent to at least two expert reviewers for unbiased, independent

and critical assessment. Reviewers are asked to provide an overall

recommendation supported by detailed comments on the quality and

originality of the science as well as the applicability and impact of

the reported results and conclusions. In addition, the scientific

validity of statistical analysis and data of clinical trial articles

will be evaluated by reviewers. Peer reviewers’ identities are kept

confidential, but authors’ information will be provided to the

reviewers. The editors endeavor to reach decisions on these papers

within four weeks from the original submission date. We allow authors

two weeks for general revision and one month for major revision.

Accepted papers will be published in print within four months of

acceptance.

Embargo Policy

Scientific

information in a manuscript which is under consideration or in press in

Cancer Biology & Medicine may not be discussed with the media

before publication. Preliminary reporting to public media, governmental

agencies, or manufacturers should not jeopardize publication, and should

be discussed with and approved by the editor in advance.

Corrections and Retractions

Corrections

to articles after online publication will only be made for errors that

compromise the scientific record, such as a mistake in an author’s name,

or that substantially impact the meaning or interpretation of the data

but that do not compromise the overall results or conclusions of the

article. A correction should be published as soon as reasonably

possible.

Retractions

refer to an article in its entirety that is the result of a pervasive

error, nonreproducible research, scientific misconduct, or duplicate

publication. In instances of retraction due to misconduct, the

corresponding author’s institute and funding agency will be notified,

according to COPE guidelines

(https://publicationethics.org/guidance/Guidelines).

Editors

may consider issuing an Editorial Expression of Concern if they have

well-founded concerns and feel that readers should be made aware of

potentially misleading information contained in an article. Scenarios in

which Editorial Expressions of Concern may be published include

prolonged investigations of very complex cases and when the concerns may

have a significant and immediate impact on public health or public

policy. An Editorial Expression of Concern may be superseded by a

subsequent Correction or Retraction, but will remain part of the

permanent published record.

Advance Online Publication

All

accepted articles will be published online (www.cancerbiomed.org)

before print as the final version after revision and editing, with a

unique digital object identifier (DOI).

Open Access

All

accepted articles will be archived as open access documents at

www.cancerbiomed.org and www.ncbi.nlm.nih.gov/pmc/journals/2000/.

Data Sharing

In

order to maintain the integrity, transparency and reproducibility of

research records, authors must make their research data openly available

either by depositing into data repositories or by publishing the data

and files as supplementary information in the journal. The journal

encourages and enables authors to share data that supports their

research publication where appropriate. To facilitate reproducibility

and data reuse, we also encourages authors to share their software,

models, algorithms, protocols, methods and other useful materials

related to the research.

MANUSCRIPT SUBMISSION

Presubmission Inquiries

Authors

interested in getting rapid feedback on whether a manuscript is likely

to be published in Cancer Biology & Medicine are encouraged to send

inquiries by e-mail (editor@cancerbiomed.org). The inquiries should at

least include an abstract and significant figures and tables. A paper

that is invited for submission after a presubmission inquiry is still

subject to editorial review to assess for external peer review.

Online Submission

We

encourage authors to submit manuscripts via our online submission and

tracking system: http://mc03.manuscriptcentral.com/cbm. Please avoid

sending your manuscript by e-mail attachment.

Questions and required documents in submission process:

● Manuscript type

● Manuscript title

● Running title with no more than 10 words

●

Full names including first and middle names of all authorsshould be

provided, the affiliation of everyone, as well as thee-mail address of

corresponding author(s) should be also included

●

Abstract is the sketch of core content of the whole paper,particularly,

it should offer the purpose of the study, themethods used, and results

and conclusions in an original article.References could not appear in

abstract, also, abbreviations andacronyms should be avoided

● At least 5 keywords should be provided on the maininformation of the paper

● A cover letter should be uploaded along with the paper (seemore details below)

● The approval from an ethics committee should be offered whenthe paper, especially original article, refers to clinical trials

● Upload PDFs or other files for Supplementary Data (if applicable)

● Answers to some other questions such as listing the reviewers recommended by author(s) and so on.

Our

online submission system will prompt you to upload the components of

your manuscript (cover letter, text, figures, supplemental data, etc.)

as separate files. Upon completion of this step, the website will build a

composite PDF file of your entire manuscript. Authors are responsible

to check the format of manuscript and quality of figures in the

converted PDF file and approve the submission.

Cover Letter

Each submission must be accompanied by a cover letter, which should contain the following information:

The title and a brief summary of the significant findings or points of the manuscript.

A statement of exclusive submission and no plagiarism or other misconducts.

A statement that the manuscript has been read and approved for submission by all the authors.

The name, address, and telephone number of the corresponding author.

Suggestions for appropriate reviewers and reviewer exclusions.

Status Inquiries

Authors

can check the status of the submitted manuscripts at any time in the

review process by accessing the system with their account and password.

Please feel free to send status queries to the editor@cancerbiomed.org.

Revision Submission  

The

revised version of manuscript should be submitted within two months

after authors receive the reviewers comments. Please contact the editor

if extra time is needed for revision. The journal generally allows only

one round of revision. Except for the revisions, authors should upload a

point-by-point response to the reviewers’ comments. Please do not

upload revised manuscripts as new submissions.

MANUSCRIPT FORMATS

Original Article

Original

Articles report significant new findings or important clinical

experience in cancer area, which have valuable implications.

● 300-word abstract

● 6,000 words of text

● 50 references or more

● 8 figures and/or tables in maximum

● Results and Discussion must not be combined.

● Additional display items may be published as supplementary information.

Editorial

Editorials

are usually invited, commenting on the leading-edge discoveries in

cancer research and significant advances on cancer diagnosis and

treatment.

● 3,000 words of text

● 10 references or more

● 3 figures and/or tables in maximum

Perspective

Perspectives

present a viewpoint on an important area of research and are written

only at the invitation of the Editorial Board. Perspectives focus on a

specific field or subfield within a larger discipline and discuss

current advances and future directions, sometimes with personal

insights.

● 3,500 words of text

● 10 references or more

● 3 figures and/or tables in maximum

Review

Reviews

discuss recent progress on topics of broad interest to cancer

researchers or cancer care professionals. Solicited reviews will also be

sent out for peer review.

● 250-word abstract

● 7,000 words of text

● 75 references or more

● 7 figures and/or tables in maximum

Minireview

Minireviews

are shorter reviews, usually based on recently published original

studies. Solicited minireviews will also be sent out for peer review.

● 200-word abstract

● 4,000 words of text

● 50 references or more

● 5 figures and/or tables in maximum

Letter to the Editor

Readers

are encouraged to comment on articles published in Cancer Biology &

Medicine, via Letters to the Editor. Letters to the editor will not

undergo peer review.

● A Letter should clearly indicate the original source.

● Response to a Letter should reference the Letter in the first paragraphs and its title should include the Letter title.

● 500 words of text

● 5 references or more

Practice Guideline

Practice

Guidelines introduce consensuses or clinical guidelines produced by

international authoritative groups or societies about cancer.

Multi-disciplinary Team (MDT) Case Study

MDT

case study integrates theragnostic analysis on representative patient

case from multi-disciplinary experiences which provides practical

information for clinicians.  

● 200-word abstract

● 3,000 words of text

● 30 references or more

● 5 figures and/or tables in maximum

MANUSCRIPT PREPARATION

Authors

should prepare their manuscripts according to the Recommendations for

the Conduct, Reporting, Editing, and Publication of Scholarly Work in

Medical Journals established by the ICMJE (http://www.icmje.org)

(http://www.icmje.org). The editors have the right to return manuscripts

that are not in accordance with the journal’s policies and format

requirements. Manuscripts must be written in concise and fluent English.

It is suggested that authors have their manuscript reviewed by

colleagues and/or by professional English language editing services

before submission.

The

manuscript of observational and experimental articles should include

title page, abstract, introduction, materials and methods, results,

discussion, acknowledgements, conflict of interest statement,

references, figures, tables, and supplementary information. All pages of

the manuscript should be numbered consecutively, beginning with the

title page.

Title Page

Title

Key information should be included in the title, which enables

electronic retrieval of the article both sensitive and specific.

The title should not contain any abbreviations except for commonly used

gene or protein acronyms. The total length of the title should not

exceed 20 words.

Authors and Affiliations For each author, the name,

mailing address, telephone and fax numbers, and e-mail address should

be indicated clearly; numbers in superscript should be used to indicate

the department, institution, city with postal code and country.

Author

Contribution Cancer Biology & Medicine requires a statement

specifying the contributions of every author on the title page.

Source(s) of Support Any support in the form of grants, equipment, drugs, or all of these should be claimed.

Running Title A running title of no more than 10 words is required.

Abstract

This

should be a single paragraph of about 250 words, accurately reflecting

the content of the article. Abbreviations and reference citation should

be avoided in the abstract. The abstract should describe all key novel

findings of the study. Structured abstracts (Objective, Methods,

Results, and Conclusion) are preferred for original research articles.

For articles on clinical trials, items identified by the CONSORT group

should be provided and the trial registration number should be listed at

the end of the abstract.

Keywords

Authors

should list keywords (up to five) which reflect the key information of

the article. Medical Subject Headings (MeSH) should be used as a guide

(http://www.nlm.nih.gov/mesh/meshhome.html).

Introduction

The

Introduction section should provide the necessary background and the

specific purpose of the research. Cite references to the most pertinent

articles and avoid including data or conclusion of the study being

reported.

Materials and Methods

Information

about materials and methods should be brief and adequate so that all

procedures can be repeated by others. Methods that have been well

described in previous publications should be merely cited with

appropriate references. Only new and substantially modified

methods need detailed explanation. The generic name (s), dose (s), and

administration route (s) of all drugs and chemicals should be precisely

identified.

Describe

statistical methods with enough details. Provide references for the

statistical methods when possible and explain whether their data conform

to the assumptions of the tests. The computer software used should be

specified. Authors should be aware that statistical analysis and

presentation is an essential part to review for all referees.

Manuscripts

involving humans and animals must include a statement in this section

that the research has been reviewed and approved by institutional

ethical committee before conduction of research. For manuscripts

involving human subjects, a statement that the informed consent was

obtained from each subject is required.

Results

The

results should be presented in logical sequence in the text, tables,

and figures, accurately describing important findings of the study.

Concisely summarize the data presented in tables and figures, avoiding

excessive explanations.

Discussion

Accurately

interpret the new and important findings of the study and discuss the

results in a broader context. Avoid repeating materials already showed

in the Introduction or the Results section. Pertinent data in previous

publications should be appropriately discussed and cited. Discuss the

limitations and implications of the study. Avoid drawing conclusions

without adequate support by the data.

Conflict of Interest Statement

In

this section, whether there is a Conflict of Interest should be stated.

Authors must disclose the details of all conflicts if there are any.

Acknowledgements

Contributions

of non-authors should be acknowledged. The corresponding author is

responsible to obtain the written permission from those mentioned in

this section. The funding sources (if any) should be listed, with grant

name and number.

References

Cancer

Biology & Medicine requires the citation of original research

articles wherever appropriate. Number the references in the order of

their first mention. References should include only articles that are

published or in press. Avoid citing abstracts, personal communication,

or retracted articles. Authors are responsible for the accuracy of

references and should ensure that the pertinent literatures are

appropriately cited and comprehensively discussed. Please use the

following style for references:

Article

in a Journal: Ulivi P, Delmonte A, Chiadini E, CalistriD, Papi M,

Mariotti M, et al. Gene mutation analysis in EGFR wild type NSCLC

responsive to erlotinib: are there features to guide patient selection?

Int J Mol Sci. 2014; 16: 747-57.

Article

in a book: Gradishar W. Male breast cancer. In: Harris J, Lippman M,

Morrow M, Osborne C, eds. Diseases of the breast. 2nd ed. Philadelphia:

Lippincott Williams & Wilkins. 2000: 661-7.

An

entire book: Bruce A. Chabner, Dan L. Longo. Cancer Chemotherapy and

Biotherapy: Principles and Practice. Philadelphia: Lippincott Williams

& Wilkins. 2006.

Online

first articles: Gregg W. Stone, Akiko Maehara, Bernhard Witzenbichler,

et al. Intracoronary Abciximab and Aspiration Thrombectomy in Patients

With Large Anterior Myocardial Infarction: The INFUSE-AMI Randomized

Trial. JAMA. Published online first: March 25, 2012. DOI:

10.1001/jama.2012.421

Tables

Type

tables on separate sheets and number them consecutively in Arabic

numerals according to the order of their first mention in the text.

Tables should be self-explanatory and include a brief descriptive title

above. Column headings should be concise, with units of measurement in

parentheses. Explain all abbreviations in footnotes and use the

following symbols, in sequence: †, ‡, §, ¶, etc. *, **, ***, etc. should

be reserved for P values.

Figures

The

number of figures for each manuscript format should not exceed the

limitation as above mentioned. Importantly, graphic models with

essential annotations and interpretations, such as pathway

illustrations, are needed when the content refers to mechanism, theory,

or core research findings, especially in review or original article.

Figures

should be labeled in consecutive Arabic numerals and presented in the

order they are mentioned in the text. If reuse of a figure in previously

publications is necessary, the author must provide the written

permission from the copyright holder and indicate the original source in

the legend.

The

figures should be submitted as separate files, in TIF, EPS, JPEG, or

GIF formats and should be sized at 127×173 mm (5×7 inches). High

resolution is preferred. At least 300 dpi for color figures and 1,000

dpi for line figures are required. Photomicrographs should have internal

scale markers. Symbols, arrows, or letters used in photomicrographs

should contrast with the background.

Figure

legends should be concise and comprehensive and be listed in a separate

page. Ensure that legends and figures match up correctly. Indicate

stains and magnifications and clearly explain symbols, arrows,

abbreviations, and letters used in the legends.

Supplementary Information

Supplementary

data should enhance, but not be essential to, a reader's understanding

of the paper. Without them, the article also must be complete and clear.

Supplementary data will also be sent out for peer review as equal in

quality as the main paper.

Supplementary files may consist of the following contents:

● Figures and/or tables

● Materials and methods mentioned in the main paper should be described in details

● Database information

● Electronic multimedia documents (e.g., videos, audios)

Restrictions on number and size of files:

● The number of supplementary files per article should not exceed 8.

● The file size should not exceed 10 MB.

Submit supplementary information as a separate file through thesubmission system.

Each

supplementary item/file must be referenced at least once in the paper.

The form of tables or figures in supplementary items should follow the

related requirements used for the manuscript, for instance, “Figure S1”

stands for supplementary Figure 1, or“Table S3” stands for supplementary Table 3.

PROOFS

Authors

whose articles are accepted will receive an e-mail with their proof

before publication. Authors should check the accuracy and the layout of

the text, tables and figures. The PDF should be clearly annotated for

necessary corrections and then returned via e-mail to

editor@cancerbiomed.org by the date indicated. Major alterations which

may delay the publication are not encouraged.

CHARGES

As

an open access journal, Cancer Biology & Medicine charges a

reasonable publication fee of $1,500/¥10,000 for each accepted article

(all article types).

No fees will be charged for invited articles.

OFFPRINTS

Offprint

order forms will be sent with the proofs. Authors who request offprints

should complete and return the forms to the editorial office before the

journal is printed. Late orders submitted after the print publication

may be subject to an increased price.

CONTACT INFORMATION

Tianjin Medical University Cancer Institute and Hospital,

Huan-hu-xi Road, He-xi District, Tianjin 300060, China

Tel: 8622-23522919

Fax: 8622-23522919

E-mail: editor@cancerbiomed.org

Website: www.cancerbiomed.org